Undisclosed

CF PharmTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.

Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: BioTrack Capital

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Series F Financing July 03, 2020

Details:

With this new round of funding, CF Pharmtech is more poised than ever to provide respiratory disease treatments for China and global market.

Citius Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Citius Receives FDA Response on Pre-Investigational New Drug Application for its Induced Mesenchymal Stem Cells

Lead Product(s): iPSC-derived MSCs

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2020

Details:

U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

University of St Andrews

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ILC Therapeutics Announces Research Partnership with University of St Andrews to Fight Against COVID-19

Lead Product(s): Alfacyte

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Alfacyte

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: ILC Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 23, 2020

Details:

The collaborative work between ILC Therapeutics and Dr. Catherine Adamson from the School of Biology at the University of St Andrews, will focus on the role that Alfacyte can play in preventing COVID-19-indusced acute respiratory distress syndrome (ARDS).

Santhera Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome

Lead Product(s): Lonodelestat

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: CSHL

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 27, 2020

Details:

Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.

Light Chain Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

Lead Product(s): NI-0101

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Edesa Biotech

Deal Size: $372.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 20, 2020

Details:

The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.

Novellus

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19

Lead Product(s): Mesenchymal stem cells

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Citius Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 01, 2020

Details:

Citius signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome from a subsidiary of Novellus.

InflaRx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19

Lead Product(s): Ifx-1

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands.

Kiniksa Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab

Lead Product(s): Mavrilimumab

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned.

Partner Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine

Lead Product(s): Sargramostim

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

Leukine can be used for treating COVID-19 induced acute hypoxic respiratory failure and ARDS in a nebulized form for immediate inhalation or by intravenous injection.

Ampio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion

Lead Product(s): Aspartyl-alanyl-diketopiperazine

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

Ampio is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 induced ADRS.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

CF PharmTech

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.

Citius Pharmaceuticals

Citius Receives FDA Response on Pre-Investigational New Drug Application for its Induced Mesenchymal Stem Cells

University of St Andrews

ILC Therapeutics Announces Research Partnership with University of St Andrews to Fight Against COVID-19

Santhera Pharmaceuticals

Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome

Light Chain Bioscience

Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

Novellus

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19

InflaRx

03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19

Kiniksa Pharmaceuticals

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab

Partner Therapeutics

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine

Ampio Pharmaceuticals

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion